BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+(TM) at SITC 2025

Stock Information for Akoya BioSciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Akoya BioSciences Inc.

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025
BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout
BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025
BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025
BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics
BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025
BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+(TM) in Breast and Prostate Cancer Models
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.